Analysts’ Ratings for Tenet Healthcare and Its Peers in March

Tenet Healthcare (THC) is a diversified healthcare services company. It operates regionally focused, integrated healthcare delivery networks in large urban and suburban markets in the United States. 

At the end of December 2017, the company operated 76 hospitals, 20 surgical hospitals, and over 470 outpatient centers in the United States and nine facilities in the United Kingdom.

Additionally, Tenet Healthcare provides healthcare business process services in the areas of hospital and physician revenue-cycle management and care solutions to healthcare systems, individual hospitals, physician practices, and health plans.

Of the 18 analysts covering Tenet Healthcare in March 2018, six have given the stock “buy” or higher ratings, ten have given it “hold” ratings, and two have given it “sell” ratings. The mean rating for the stock is 2.56 with a target price of $22.76.

Of the four analysts covering Civitas Solutions (CIVI) in March 2018, two have given the stock “strong buy” ratings, and two have given it “buy” ratings. The mean rating for the stock is 1.5 with a target price of $18.75.

In March 2018, six of the 22 analysts covering Merck & Co. (MRK) have given the stock “strong buy” ratings. Seven analysts have given it “buy” ratings, and nine have given it “hold” ratings. The mean rating for the stock is 2.14 with a target price of $66.24.

Of the 23 analysts covering Pfizer (PFE) in March 2018, 12 analysts have given the stock “buy” or higher ratings. Nine analysts have given it “hold” ratings, and two analysts have given it “strong sell” ratings. The mean rating for the stock is 2.57 with a target price of $40.2.

In the next part of the series, we’ll take a look at the steps Tenet Healthcare is taking to navigate the current industry challenges.